Anti-CFH Antibody - Machaon Diagnostics
New test available: mHam 2.0 – Complement-Dependent Cell Killing Assay

Test Directory

Home Test Search Results Anti-CFH Antibody
Anti-CFH Antibody

Justification

Factor H is a regulator of the alternative complement activation pathway. Acquired Factor H deficiency due to autoantibody production can lead to overactive complement. Continuous complement activation is associated with development of atypical Hemolytic Uremic Syndrome (aHUS) and Dense Deposit Disease (DDD).

STAT: < 48 hours (M-F)

ELISA

Draw Tube: Red Top

Sample Type: Serum

Draw Kits Available

Test Summary

Specimen Requirements

Sample Type Volume Required Minimum Volume Stability
PREFERRED Serum 1mL 0.5mL Room Temp.: 7 days
Refrigerated: 7 days
Frozen (-20C): 2 weeks
Frozen (-80C): 6 months
ALTERNATIVE - - - -
REJECTION CRITERIA Thawed in transit if shipped frozen, refrozen, clotted sample
SPECIAL INSTRUCTIONS -

General Information

METHODOLOGY ELISA
STAT TAT < 48 hours (M-F)
STAT TAT Performance > 90% of results released in 48 hours
ROUTINE TAT < 5 days (M-F)
ALTERNATIVE NAMES Anti-Complement Factor H Antibody, Complement Factor H Autoantibody; complement-mediated HUS; cm-HUS
DESCRIPTION Chromogenic ELISA for the quantitative detection of anti-complement factor H (CFH) antibodies.
LIMITATIONS Anti-CFH autoantibody levels may be significantly reduced by treatments such as plasmapheresis, rituximab, or cyclophosphamide therapy (Khandelwal (2015) Pediatr Nephrol 30, 3).
NORMAL RANGE < 20 Units/mL
ASSOCIATED TESTING -
REFERENCES

1. Dragon-Durey M, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-563.
2. Dragon-Durey M, Sethi SK, Bagga A, et al.Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010;21:2180-2187.
SAMPLE REPORT Upon request
NEW YORK STATE APPROVED Yes

Test Codes

ORDER CODE P3358
CPT CODE 83516
LOINC CODE 4519-5